Skip to main content
SpringerLink
Log in

An Update on Drug-Induced Pigmentation

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Drug-induced pigmentation accounts for up to 20% of all cases of acquired pigmentation. A thorough review of medical history and previous and ongoing medications as well as a complete skin examination can guide diagnosis. Implicated agents include alkylating/cytotoxic agents, analgesics, antiarrhythmics, anticoagulants, antiepileptics, antimalarials, antimicrobials, antiretrovirals, metals, prostaglandin analogs, and psychotropic agents, among others. Confirming true drug associations can be challenging, especially in the setting of delayed onset of pigmentation and coexisting polypharmacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2:253–62.

    Article  CAS  PubMed  Google Scholar 

  2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.

    Article  CAS  PubMed  Google Scholar 

  3. Granstein RD, Sober AJ. Drug- and heavy metal–induced hyperpigmentation. J Am Acad Dermatol. 1981;5:1–18.

    Article  CAS  PubMed  Google Scholar 

  4. Delage C, Lagace R, Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J. 1975;112:1205–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Alinovi A, Reverberi C, Melissari M, Gabrielli M. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. J Am Acad Dermatol. 1985;12:563–6.

    Article  CAS  PubMed  Google Scholar 

  6. Kounis NG, Frangides C, Papadaki PJ, Zavras GM, Goudevenos J. Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Clin Cardiol. 1996;19:592–4.

    Article  CAS  PubMed  Google Scholar 

  7. Rappersberger K, Honigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Investig Dermatol. 1989;93:201–9.

    Article  CAS  PubMed  Google Scholar 

  8. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. J Am Acad Dermatol. 1998;38:201–6.

    Article  CAS  PubMed  Google Scholar 

  9. Scherschun L, Lee MW, Lim HW. Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases. Arch Dermatol. 2001;137:179–82.

    CAS  PubMed  Google Scholar 

  10. Desai N, Alexis AF, DeLeo VA. Facial hyperpigmentation caused by diltiazem hydrochloride. Cutis. 2010;86:82–4.

    PubMed  Google Scholar 

  11. Jaka A, Lopez-Pestana A, Tuneu A, Lobo C, Lopez-Nunez M, Ormaechea N. Letter: Photodistributed reticulated hyperpigmentation related to diltiazem. Dermatol Online J. 2011;17:14.

    PubMed  Google Scholar 

  12. Campbell M, Ahluwalia J, Watson AC. Diltiazem-associated hyperpigmentation. J Gen Intern Med. 2013;28:1676.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol. 2010;37:807–11.

    Article  PubMed  Google Scholar 

  14. Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(902–10):e2.

    Google Scholar 

  15. Rao R, Balachandran C. Serpentine supravenous pigmentation. A rare vasculo-cutaneous effect induced by systemic 5-fluorouracil. Indian J Dermatol Venereol Leprol. 2010;76:714–5.

    Article  PubMed  Google Scholar 

  16. Pujol RM, Rocamora V, Lopez-Pousa A, Taberner R, Alomar A. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol. 1998;39:839–42.

    Article  CAS  PubMed  Google Scholar 

  17. Allen BJ, Parker D, Wright AL. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol. 1995;34:219–20.

    Article  CAS  PubMed  Google Scholar 

  18. Hrushesky WJ. Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA. 1976;236:138.

    Article  CAS  PubMed  Google Scholar 

  19. Lee HY, Lim KH, Ryu Y, Song SY. Bleomycin-induced flagellate erythema: a case report and review of the literature. Oncol Lett. 2014;8:933–5.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Rubeiz NG, Salem Z, Dibbs R, Kibbi AG. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol. 1999;38:140–1.

    Article  CAS  PubMed  Google Scholar 

  21. Templeton SF, Solomon AR, Swerlick RA. Intradermal bleomycin injections into normal human skin. A histopathologic and immunopathologic study. Arch Dermatol. 1994;130:577–83.

    Article  CAS  PubMed  Google Scholar 

  22. Watanabe T, Tsuchida T. ‘Flagellate’ erythema in dermatomyositis. Dermatology. 1995;190:230–1.

    Article  CAS  PubMed  Google Scholar 

  23. Cortina P, Garrido JA, Tomas JF, Unamuno P, Armijo M. ‘Flagellate’ erythema from bleomycin. With histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990;180:106–9.

    Article  CAS  PubMed  Google Scholar 

  24. Fernandez-Obregon AC, Hogan KP, Bibro MK. Flagellate pigmentation from intrapleural bleomycin. A light microscopy and electron microscopy study. J Am Acad Dermatol. 1985;13:464–8.

    Article  CAS  PubMed  Google Scholar 

  25. Pinto C, Lorca-Garcia C, Berenguer B, De Tomas Palacios ME. Bleomycin-induced flagellate erythema after venous malformation sclerosis—case report and brief review. Pediatr Dermatol. 2018;35:e5–8.

    Article  PubMed  Google Scholar 

  26. Fitzpatrick JE, Yobel DE, Hood AF. Mucocutaneous complications of antineoplastic therapy. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw Hill; 1999. p. 1642–53.

    Google Scholar 

  27. Kumar S, Dixit R, Karmakar S, Paul S. Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen. Indian J Pharmacol. 2010;42:243–4.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ranawaka RR. Patterns of chromonychia during chemotherapy in patients with skin type V and outcome after 1 year of follow-up. Clin Exp Dermatol. 2009;34:e920–6.

    Article  CAS  PubMed  Google Scholar 

  29. Casamiquela KM, Cohen PR. Chemotherapy-associated tongue hyperpigmentation and blue lunula. J Drugs Dermatol. 2013;12:223–6.

    PubMed  Google Scholar 

  30. Daniel CR 3rd, Scher RK. Nail changes caused by systemic drugs or ingestants. Dermatol Clin. 1985;3:491–500.

    Article  PubMed  Google Scholar 

  31. Teresi ME, Murry DJ, Cornelius AS. Ifosfamide-induced hyperpigmentation. Cancer. 1993;71:2873–5.

    Article  CAS  PubMed  Google Scholar 

  32. Lever W, Schaumburg-Lever G. Histopathology of the skin. 5th ed. Philadelphia: J.B. Lippincott Co; 1975.

    Google Scholar 

  33. Morris D, Aisner J, Wiernik PH. Horizontal pigmented banding of the nails in association with adriamycin chemotherapy. Cancer Treat Rep. 1977;61:499–501.

    CAS  PubMed  Google Scholar 

  34. Priestman TJ, James KW. Letter: Adriamycin and longitudinal pigmented banding of fingernails. Lancet (London, England). 1975;1:1337–8.

    Article  CAS  Google Scholar 

  35. Pratt CB, Shanks EC. Letter: Hyperpigmentation of nails from doxorubicin. JAMA. 1974;228:460.

    Article  CAS  PubMed  Google Scholar 

  36. Rothberg H, Place CH, Shteir O. Adriamycin (NSC-123127) toxicity: unusual melanotic reaction. Cancer Chemother Rep. 1974;58:749–51.

    CAS  PubMed  Google Scholar 

  37. Rao SP, Potnis AV, Sobrinho TC, Brown AK. Pigmentation of the tongue after treatment with adriamycin. Cancer Treat Rep. 1976;60:1402–4.

    CAS  PubMed  Google Scholar 

  38. Tosti A, Baran R, Dawber RPR. The nail in systemic diseases and drug-induced changes. In: Baran R, Dawber RPR, editors. Diseases of the nails and their management. 2nd ed. Oxford: Blackwell Scientific Publications; 1994.

    Google Scholar 

  39. Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:4646–8.

    Article  PubMed  Google Scholar 

  40. Jalalat SZ, Cohen PR. Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation. Dermatol Online J. 2013;19:20020.

    PubMed  Google Scholar 

  41. Aste N, Fumo G, Contu F, Aste N, Biggio P. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol. 2002;47:146–7.

    Article  PubMed  Google Scholar 

  42. Kumar A, Gupta S, Mohanty S, Bhargava B, Airan B. Stem cell niche is partially lost during follicular plucking: a preliminary pilot study. Int J Trichology. 2013;5:97–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol. 2002;27:8–13.

    Article  CAS  PubMed  Google Scholar 

  44. Cakir B, Sucak G, Haznedar R. Longitudinal pigmented nail bands during hydroxyurea therapy. Int J Dermatol. 1997;36:236–7.

    Article  CAS  PubMed  Google Scholar 

  45. Delmas-Marsalet B, Beaulieu P, Teillet-Thiebaud F, Jary L, Teillet F. Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Nouvelle Revue Francaise d’hematologie. 1995;37:205–10.

    CAS  PubMed  Google Scholar 

  46. Jeevankumar B, Thappa DM. Blue lunula due to hydroxyurea. J Dermatol. 2003;30:628–30.

    Article  PubMed  Google Scholar 

  47. Uskudar Teke H, Erden A. Blue lunula related with hydroxyurea. Turk J Haematol. 2013;30:100–1.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Vomvouras S, Pakula AS, Shaw JM. Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding. J Am Acad Dermatol. 1991;24:1016–7.

    Article  CAS  PubMed  Google Scholar 

  49. Baran R, Kechijian P. Longitudinal melanonychia (melanonychia striata): diagnosis and management. J Am Acad Dermatol. 1989;21:1165–75.

    Article  CAS  PubMed  Google Scholar 

  50. Sulis E, Floris C. Nail pigmentation following cancer chemotherapy. A new genetic entity? Eur J Cancer. 1980;16:1517–9.

    Article  CAS  PubMed  Google Scholar 

  51. Nguyen AL, Korver JE, Theunissen CC. Longitudinal melanonychia on multiple nails induced by hydroxyurea. BMJ Case Rep. 2017;2017:bcr2016218644.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Balagula Y, Pulitzer MP, Maki RG, Myskowski PL. Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol. 2011;10:1062–6.

    PubMed  Google Scholar 

  53. Singh N, Bakhshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol. 2007;29:208–9.

    Article  PubMed  Google Scholar 

  54. Singh O, Agrawal P, Agarwal A, Yadav S. Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in adult female. J Assoc Physicians India. 2016;64:138.

    Google Scholar 

  55. Agrawal P, Singh O, Nigam AK, Upadhyay S. Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female. Indian J Pharmacol. 2015;47:685–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bombeccari GP, Garagiola U, Pallotti F, Rossi M, Porrini M, Gianni AB, et al. Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib. Maxillofac Plast Reconstr Surg. 2017;39:37.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008;14:7.

    PubMed  Google Scholar 

  58. Mattsson U, Halbritter S, Morner Serikoff E, Christerson L, Warfvinge G. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:e12–6.

    Article  CAS  PubMed  Google Scholar 

  59. Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol. 2012;6:290–5.

    Article  PubMed  Google Scholar 

  60. Di Tullio F, Mandel VD, Scotti R, Padalino C, Pellacani G. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature. Int J Dermatol. 2018;57:784–90.

    Article  PubMed  Google Scholar 

  61. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15:358–9.

    Article  CAS  PubMed  Google Scholar 

  62. Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol. 2006;72:63–4.

    Article  CAS  PubMed  Google Scholar 

  63. McPherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009;23:82–3.

    Article  CAS  PubMed  Google Scholar 

  64. Lewis DM. Diffuse pigmentation of the palate. J Oklahoma Dent Assoc. 2009;100:24–5.

    Google Scholar 

  65. Wong M, Sade S, Gilbert M, Klieb HB. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Dermatol Online J. 2011;17:4.

    PubMed  Google Scholar 

  66. Steele JC, Triantafyllou A, Rajlawat BP, Field EA. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib. Clin Exp Dermatol. 2012;37:432–3.

    Article  CAS  PubMed  Google Scholar 

  67. Resende RG, Teixeira RG, Vasconcelos Fde O, Silva ME, Abreu MH, Gomez RS. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Cranio-Maxillo-Fac Surg. 2012;40:e140–3.

    Article  Google Scholar 

  68. Khoo TL, Catalano A, Supple S, Chong L, Yeoh SC, Yeung S, et al. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leuk Lymphoma. 2013;54:186–8.

    Article  CAS  PubMed  Google Scholar 

  69. Roeker LE, Wolanskyj AP. Imatinib-associated melanosis of the palate. Am J Hematol. 2014;89:564.

    Article  CAS  PubMed  Google Scholar 

  70. Song HS, Kang HY. Imatinib mesylate-induced hyperpigmentation of the nose and palate. Ann Dermatol. 2014;26:532–3.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Lyne A, Creedon A, Bailey BM. Mucosal pigmentation of the hard palate in a patient taking imatinib. BMJ Case Rep. 2015;2015:bcr2015209335.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Balasubramanian P, Jagadeesan S, Thomas J. Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia. Indian J Dermatol. 2015;60:523.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Romeo U, Palaia G, Fantozzi PJ, Tenore G, Bosco D. A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia. Case Rep Dent. 2015;2015:817094.

    PubMed  PubMed Central  Google Scholar 

  74. Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma-like pigmentation: report of five cases and review of literature. Indian J Dermatol Venereol Leprol. 2016;82:409–12.

    Article  PubMed  Google Scholar 

  75. Llamas-Velasco M, Fraga J, Kutzner H, Steegmann JL, Garcia-Diez A, Requena L. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. J Cutan Pathol. 2014;41:417–26.

    Article  PubMed  Google Scholar 

  76. McPartlin S, Leach M. Loss of skin pigment caused by imatinib therapy. Br J Haematol. 2005;129:448.

    Article  CAS  PubMed  Google Scholar 

  77. Tsao AS, Kantarjian H, Cortes J, O’Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98:2483–7.

    Article  PubMed  Google Scholar 

  78. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48:201–6.

    Article  PubMed  Google Scholar 

  79. Brazzelli V, Prestinari F, Barbagallo T, Rona C, Orlandi E, Passamonti F, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol. 2007;21:384–7.

    Article  CAS  PubMed  Google Scholar 

  80. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol. 2003;120:911–3.

    Article  CAS  PubMed  Google Scholar 

  81. Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004;100:2486–7 (author reply 7–8).

    Article  PubMed  Google Scholar 

  82. Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases. 2016;4:390–400.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, et al. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology. 2015;231:312–8.

    Article  CAS  PubMed  Google Scholar 

  84. Schallier D, Decoster L, de Greve J. Pemetrexed-induced hyperpigmentation of the skin. Anticancer Res. 2011;31:1753–5.

    CAS  PubMed  Google Scholar 

  85. Dasanu CA, Wiernik PH, Vaillant J, Alexandrescu DT. A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer. Skinmed. 2007;6:95–6.

    Article  PubMed  Google Scholar 

  86. Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100:328–30.

    Article  PubMed  Google Scholar 

  87. Espinosa Lara P, Bueno C, Aranegui B, Vargas-Machuca I, Jimenez Reyes J. Yellowish nail pigmentation caused by sunitinib. Int J Dermatol. 2016;55:e462–3.

    Article  PubMed  Google Scholar 

  88. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol. 2014;71:217 e1–e11 (quiz 27-8).

    Google Scholar 

  89. Ishak RS, Aad SA, Kyei A, Farhat FS. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors. Crit Rev Oncol Hematol. 2014;90:152–64.

    Article  PubMed  Google Scholar 

  90. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35.

    Article  CAS  PubMed  Google Scholar 

  91. Teixeira V, Vieira R, Figueiredo A. Tegafur-induced acral hyperpigmentation. Dermatol Rep. 2011;3:e30.

    Article  CAS  Google Scholar 

  92. Llistosella E, Codina A, Alvarez R, Pujol RM, de Moragas JM. Tegafur-induced acral hyperpigmentation. Cutis. 1991;48:205–7.

    CAS  PubMed  Google Scholar 

  93. Fukushima S, Hatta N. Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. Br J Dermatol. 2004;151:698–700.

    Article  CAS  PubMed  Google Scholar 

  94. Braunstein I, Wanat KA, Elenitsas R, Xu X, Frey N, Rosenbach M. Eltrombopag-associated hyperpigmentation. JAMA Dermatol. 2013;149:1112–5.

    Article  PubMed  Google Scholar 

  95. Bowen CJ, Lobb KM, Park JW, Sanderson B, Ferguson J. Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. Photodermatol Photoimmunol Photomed. 2010;26:243–9.

    Article  CAS  PubMed  Google Scholar 

  96. Takci Z, Ozoguz P. Nail discoloration due to tinzaparin sodium. Cutan Ocul Toxicol. 2012;31:332–4.

    Article  PubMed  Google Scholar 

  97. Scheinfeld N. Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol Online J. 2003;9:6.

    PubMed  Google Scholar 

  98. Namazi MR. Phenytoin as a novel anti-vitiligo weapon. J Autoimmune Dis. 2005;2:11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Bleehen SS. Disorders of skin color. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. London: Blackwell Scientific Publications; 1998. p. 1785.

    Google Scholar 

  100. Smith DA, Burgdorf WH. Universal cutaneous depigmentation following phenytoin-induced toxic epidermal necrolysis. J Am Acad Dermatol. 1984;10:106–9.

    Article  CAS  PubMed  Google Scholar 

  101. Garin Shkolnik T, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150:984–9.

    Article  CAS  PubMed  Google Scholar 

  102. Mathias SV, Abou-Khalil BW. Ezogabine skin discoloration is reversible after discontinuation. Epilepsy Behav Case Rep. 2017;7:61–3.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Beacher NG, Brodie MJ, Goodall C. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate. BMC Oral Health. 2015;15:122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. King M. Management of Tyndall effect. J Clin Aesthet Dermatol. 2016;9:E6–8.

    PubMed  PubMed Central  Google Scholar 

  105. Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006;38:202–4.

    Article  PubMed  Google Scholar 

  106. Skare T, Ribeiro CF, Souza FH, Haendchen L, Jordao JM. Antimalarial cutaneous side effects: a study in 209 users. Cutan Ocul Toxicol. 2011;30:45–9.

    Article  PubMed  Google Scholar 

  107. Gallo CB, Luiz AC, Ferrazzo KL, Migliari DA, Sugaya NN. Drug-induced pigmentation of hard palate and skin due to chronic chloroquine therapy: report of two cases. Clin Exp Dermatol. 2009;34:e266–7.

    Article  CAS  PubMed  Google Scholar 

  108. Brasil Cda M, Ribeiro CM, Fonseca DD, Gueiros LA, Leao JC. Chloroquine-induced hyperpigmentation of the hard palate. Gen Dent. 2012;60:e74–8.

    PubMed  Google Scholar 

  109. Bahloul E, Jallouli M, Garbaa S, Marzouk S, Masmoudi A, Turki H, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017;26:1304–8.

    Article  CAS  PubMed  Google Scholar 

  110. Cohen PR. Hydroxychloroquine-associated hyperpigmentation mimicking elder abuse. Dermatol Ther. 2013;3:203–10.

    Article  Google Scholar 

  111. Puri PK, Lountzis NI, Tyler W, Ferringer T. Hydroxychloroquine-induced hyperpigmentation: the staining pattern. J Cutan Pathol. 2008;35:1134–7.

    Article  PubMed  Google Scholar 

  112. Rood MJ, Vermeer MH, Huizinga TW. Hyperpigmentation of the skin due to hydroxychloroquine. Scand J Rheumatol. 2008;37:158.

    Article  CAS  PubMed  Google Scholar 

  113. Sams WM Jr, Epstein JH. The affinity of melanin for chloroquine. J Investig Dermatol. 1965;45:482–7.

    Article  PubMed  Google Scholar 

  114. Melikoglu MA, Melikoglu M, Gurbuz U, Budak BS, Kacar C. Hydroxychloroquine-induced hyperpigmentation: a case report. J Clin Pharm Ther. 2008;33:699–701.

    Article  CAS  PubMed  Google Scholar 

  115. Ribrioux A. Synthetic antimalarials and skin [in French]. Ann Dermatol Venereol. 1990;117:975–90.

    CAS  PubMed  Google Scholar 

  116. United States Pharmacopeial Convention. Drug information for the health care professional. 19th ed. Englewood: Micromedex, Inc; 1999.

    Google Scholar 

  117. Karat AB, Jeevaratnam A, Karat S, Rao PS. Controlled clinical trial of clofazimine in untreated lepromatous leprosy. Br Med J. 1971;4:514–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Murashov MD, LaLone V, Rzeczycki PM, Keswani RK, Yoon GS, Sud S, et al. The physicochemical basis of clofazimine-induced skin pigmentation. J Investig Dermatol. 2018;138:697–703.

    Article  CAS  PubMed  Google Scholar 

  119. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60:1361–7.

    Article  PubMed  Google Scholar 

  120. Burke P, Jahangir K, Kolber MR. Dapsone-induced methemoglobinemia: case of the blue lady. Can Family Physician. 2013;59:958–61.

    Google Scholar 

  121. Bilgili SG, Karadag AS, Calka O, Altun F. Isoniazid-induced pellagra. Cutan Ocul Toxicol. 2011;30:317–9.

    Article  CAS  PubMed  Google Scholar 

  122. Pitt F. Tuberculosis, prevention and therapy. In: Hook EWMG, Gwatney JM, et al., editors. Current concepts of infection sdisease. New York: Wiley; 1977. p. 181–94.

    Google Scholar 

  123. Gourishankar A, Navarro F, Debroy AN, Smith KC. Isoniazid hepatotoxicity with clinical and histopathology correlate. Ann Clin Lab Sci. 2014;44:87–90.

    PubMed  Google Scholar 

  124. Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol. 1985;24:280–5.

    Article  CAS  PubMed  Google Scholar 

  125. Lorente M, Ballano A, Juanes A, Pastor MA, Cuevas J. Blue-gray pigmentation in trunk and extremities in a 71-year-old man. JAMA Dermatol. 2013;149:1111–2.

    Article  PubMed  Google Scholar 

  126. Lopez-Pestana A, Tuneu A, Lobo C, Zubizarreta J, Eguino P. Blue-black pigmentation of legs and arms in a 68-year-old woman. Arch Dermatol. 2007;143:1441–6.

    Article  PubMed  Google Scholar 

  127. Le Cleach L, Chosidow O, Peytavin G, Berry JP, Boisnic S, Le Charpentier Y, et al. Blue-black pigmentation of the legs associated with pefloxacin therapy. Arch Dermatol. 1995;131:856–7.

    Article  PubMed  Google Scholar 

  128. McGrae JD Jr, Zelickson AS. Skin pigmentation secondary to minocycline therapy. Arch Dermatol. 1980;116:1262–5.

    Article  PubMed  Google Scholar 

  129. Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol. 1980;3:244–7.

    Article  CAS  PubMed  Google Scholar 

  130. Patel K, Cheshire D, Vance A. Oral and systemic effects of prolonged minocycline therapy. Br Dent J. 1998;185:560–2.

    Article  CAS  PubMed  Google Scholar 

  131. Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf. 1998;18:431–40.

    Article  CAS  PubMed  Google Scholar 

  132. Fraunfelder FT, Randall JA. Minocycline-induced scleral pigmentation. Ophthalmology. 1997;104:936–8.

    Article  CAS  PubMed  Google Scholar 

  133. Pepine M, Flowers FP, Ramos-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol. 1993;28:292–5.

    Article  CAS  PubMed  Google Scholar 

  134. Alkhatib AA, Sessoms S. The tarnished tongue. Am J Med. 2006;119:832–4.

    Article  PubMed  Google Scholar 

  135. Meyerson MA, Cohen PR, Hymes SR. Lingual hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79:180–4.

    Article  CAS  PubMed  Google Scholar 

  136. Tanzi EL, Hecker MS. Minocycline-induced hyperpigmentation of the tongue. Arch Dermatol. 2000;136:427–8.

    Article  CAS  PubMed  Google Scholar 

  137. Katz J, Barak S, Shemer J, Langevitz P, Livneh A. Black tongue associated with minocycline therapy. Arch Dermatol. 1995;131:620.

    Article  CAS  PubMed  Google Scholar 

  138. Friedman IS, Shelton RM, Phelps RG. Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. Dermatol Surg. 2002;28:205–9.

    PubMed  Google Scholar 

  139. Basler RS. Minocycline therapy for acne. Arch Dermatol. 1979;115:1391.

    Article  CAS  PubMed  Google Scholar 

  140. Lahiry S, Choudhury S, Mukherjee A, Bhunya PK, Bala M. Polymyxin B-induced diffuse cutaneous hyperpigmentation. J Clin Diagn Res. 2017;11:fd1–2.

    Article  Google Scholar 

  141. Bushby SR, Green AF. The release or histamine by polymyxin B and polymyxin E. Br J Pharmacol Chemother. 1955;10:215–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Salazar de Sousa J, Almeida V, Bray Pinheiro J. Red child syndrome. Arch Dis Child. 1987;62:1181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Shirasaka T, Tadokoro T, Yamamoto Y, Fukutake K, Kato Y, Odawara T, et al. Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. J Infect Chemother. 2011;17:602–8.

    Article  CAS  PubMed  Google Scholar 

  144. Mondou E, Hinkle J, Shaw A, Quinn J, Adda N, Rosseau F. Incidence of skin discoloration across phase 3 clinical trials of emtricitabine (FTC) in adults. In: International AIDS conference, Bangkok; 2004.

  145. Furth PA, Kazakis AM. Nail pigmentation changes associated with azidothymidine (zidovudine). Ann Intern Med. 1987;107:350.

    Article  CAS  PubMed  Google Scholar 

  146. Rahav G, Maayan S. Nail pigmentation associated with zidovudine: a review and report of a case. Scand J Infect Dis. 1992;24:557–61.

    Article  CAS  PubMed  Google Scholar 

  147. Chawre SM, Pore SM, Nandeshwar MB, Masood NM. Zidovudine-induced nail pigmentation in a 12-year-old boy. Indian J Pharmacol. 2012;44:801–2.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Greenberg RG, Berger TG. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol. 1990;22:327–30.

    Article  CAS  PubMed  Google Scholar 

  149. Panwalker AP. Nail pigmentation in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987;107:943–4.

    Article  CAS  PubMed  Google Scholar 

  150. Fisher CA, McPoland PR. Azidothymidine-induced nail pigmentation. Cutis. 1989;43:552–4.

    CAS  PubMed  Google Scholar 

  151. Singh SK, Rai T. A case of zidovudine induced pigmentation on palms and soles. Indian Dermatol Online J. 2014;5:98–9.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Cohen PR. Black tongue secondary to bismuth subsalicylate: case report and review of exogenous causes of macular lingual pigmentation. J Drugs Dermatol. 2009;8:1132–5.

    PubMed  Google Scholar 

  153. Bierer DW. Bismuth subsalicylate: history, chemistry, and safety. Rev Infect Dis. 1990;12(Suppl 1):S3–8.

    Article  CAS  PubMed  Google Scholar 

  154. Ioffreda MD, Gordon CA, Adams DR, Naides SJ, Miller JJ. Black tongue. Arch Dermatol. 2001;137:968–9.

    CAS  PubMed  Google Scholar 

  155. Bradley B, Singleton M, Lin Wan Po A. Bismuth toxicity—a reassessment. J Clin Pharm Ther. 1989;14:423–41.

    Article  CAS  PubMed  Google Scholar 

  156. Smith RW, Leppard B, Barnett NL, Millward-Sadler GH, McCrae F, Cawley MI. Chrysiasis revisited: a clinical and pathological study. Br J Dermatol. 1995;133:671–8.

    Article  CAS  PubMed  Google Scholar 

  157. Trotter MJ, Tron VA, Hollingdale J, Rivers JK. Localized chrysiasis induced by laser therapy. Arch Dermatol. 1995;131:1411–4.

    Article  CAS  PubMed  Google Scholar 

  158. Cremer B, Czarnetzki BM. Skin discolorations under gold jewelry [in German]. Dtsch Med Wochenschr. 1946;1992(117):558.

    Google Scholar 

  159. Culora GA, Barnett N, Theaker JM. Artefacts in electron microscopy: ultrastructural features of chrysiasis. J Pathol. 1995;176:421–5.

    Article  CAS  PubMed  Google Scholar 

  160. Drakensjo IT, Lengstam I, Hedblad MA. Skin discoloration caused by iron salts. Acta Derm Venereol. 2014;94:92–3.

    Article  PubMed  Google Scholar 

  161. White MI. Localized argyria caused by silver earrings. Br J Dermatol. 1997;136:980.

    Article  CAS  PubMed  Google Scholar 

  162. Legat FJ, Goessler W, Schlagenhaufen C, Soyer HP. Argyria after short-contact acupuncture. Lancet (London, England). 1998;352:241.

    Article  CAS  Google Scholar 

  163. Suzuki H, Baba S, Uchigasaki S, Murase M. Localized argyria with chrysiasis caused by implanted acupuncture needles. Distribution and chemical forms of silver and gold in cutaneous tissue by electron microscopy and X-ray microanalysis. J Am Acad Dermatol. 1993;29:833–7.

    Article  CAS  PubMed  Google Scholar 

  164. Ryu HJ, Yoon SJ, Park JT, Kim YH, Jung JM, Park MH, et al. Skin discolouration with acute onset parkinsonism secondary to systemic zirconium intoxication. Ann Clin Biochem. 2014;51:97–100.

    Article  PubMed  Google Scholar 

  165. Bleehen SS, Gould DJ, Harrington CI, Durrant TE, Slater DN, Underwood JC. Occupational argyria; light and electron microscopic studies and X-ray microanalysis. Br J Dermatol. 1981;104:19–26.

    Article  CAS  PubMed  Google Scholar 

  166. Rodriguez V, Romaguera RL, Heidecker B. Silver-containing wound cream leading to argyria—always ask about alternative health products. Am J Med. 2017;130:e145–6.

    Article  PubMed  Google Scholar 

  167. Kwon HB, Lee JH, Lee SH, Lee AY, Choi JS, Ahn YS. A case of argyria following colloidal silver ingestion. Ann Dermatol. 2009;21:308–10.

    Article  PubMed  PubMed Central  Google Scholar 

  168. White JM, Powell AM, Brady K, Russell-Jones R. Severe generalized argyria secondary to ingestion of colloidal silver protein. Clin Exp Dermatol. 2003;28:254–6.

    Article  CAS  PubMed  Google Scholar 

  169. Priluck JC, Fu S. Latisse-induced periocular skin hyperpigmentation. Arch Ophthalmol. 2010;128:792–3.

    Article  PubMed  Google Scholar 

  170. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544–7.

    Article  CAS  PubMed  Google Scholar 

  171. Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 2005;123:1541–6.

    Article  PubMed  Google Scholar 

  172. Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol. 2004;48:602–12.

    Article  CAS  PubMed  Google Scholar 

  173. Sodhi PK, Verma L, Ratan SK. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2004;137:783.

    PubMed  Google Scholar 

  174. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19:231–48.

    Article  CAS  PubMed  Google Scholar 

  175. Lin M, Schmutz M, Mosaed S. Latanoprost-induced skin depigmentation. J Glaucoma. 2017;26:e246–8.

    Article  PubMed  Google Scholar 

  176. Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007;32:1037–43.

    Article  CAS  PubMed  Google Scholar 

  177. Wolf ME, Richer S, Berk MA, Mosnaim AD. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol. 1993;31:365–7.

    CAS  PubMed  Google Scholar 

  178. Molina-Ruiz AM, Pulpillo A, Molina-Ruiz RM, Sagrario T, Requena L. Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia. Int J Dermatol. 2016;55:909–12.

    Article  PubMed  Google Scholar 

  179. Molina-Ruiz AM, Cerroni L, Kutzner H, Requena L. Cutaneous deposits. Am J Dermatopathol. 2014;36:1–48.

    Article  PubMed  Google Scholar 

  180. Buckley C, Thomas V, Lewin J, Harris D, Rustin MH. Stelazine-induced pigmentation. Clin Exp Dermatol. 1994;19:149–51.

    Article  CAS  PubMed  Google Scholar 

  181. Eichenfield DZ, Cohen PR. Amitriptyline-induced cutaneous hyperpigmentation: case report and review of psychotropic drug-associated mucocutaneous hyperpigmentation. Dermatol Online J. 2016;22:27267189.

    Google Scholar 

  182. Sicari MC, Lebwohl M, Baral J, Wexler P, Gordon RE, Phelps RG. Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol. 1999;40:290–3.

    Article  CAS  PubMed  Google Scholar 

  183. Hare PJ. “Visage mauve” (? from imipramine). Br J Dermatol. 1970;83:420.

    Article  CAS  PubMed  Google Scholar 

  184. Basler RS, Goetz CS. Synergism of minocycline and amitriptyline in cutaneous hyperpigmentation. J Am Acad Dermatol. 1985;12:577.

    Article  CAS  PubMed  Google Scholar 

  185. Basler RS, Kohnen PW. Localized hemosiderosis as a sequela of acne. Arch Dermatol. 1978;114:1695–7.

    Article  CAS  PubMed  Google Scholar 

  186. Narurkar V, Smoller BR, Hu CH, Bauer EA. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol. 1993;129:474–6.

    Article  CAS  PubMed  Google Scholar 

  187. D’Agostino ML, Risser J, Robinson-Bostom L. Imipramine-induced hyperpigmentation: a case report and review of the literature. J Cutan Pathol. 2009;36:799–803.

    Article  PubMed  Google Scholar 

  188. Steele TE, Ashby J. Desipramine-related slate-gray skin pigmentation. J Clin Psychopharmacol. 1993;13:76–7.

    Article  CAS  PubMed  Google Scholar 

  189. Blomberg M, Zachariae CO, Gronhoj F. Hyperpigmentation of the face following adalimumab treatment. Acta Derm Venereol. 2009;89:546–7.

    Article  PubMed  Google Scholar 

  190. Santos-Juanes J, Coto P, Mallo S, Galache C, Sanchez del Rio J, Torre JC. Multiple lentigines confined to resolving psoriatic plaques in a patient treated with adalimumab. Dermatology. 2008;216:279.

    Article  PubMed  Google Scholar 

  191. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172:1601–12.

    Article  CAS  PubMed  Google Scholar 

  192. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-d-Phe7]-alpha-MSH. Br J Dermatol. 2011;164:407–14.

    Article  CAS  PubMed  Google Scholar 

  194. Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149:68–73.

    Article  CAS  PubMed  Google Scholar 

  195. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56:815–23.

    Article  CAS  PubMed  Google Scholar 

  196. Lane AM, McKay JT, Bonkovsky HL. Advances in the management of erythropoietic protoporphyria—role of afamelanotide. Appl Clin Genet. 2016;9:179–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  197. Lascari AD. Carotenemia. A review. Clin Pediatr. 1981;20:25–9.

    Article  CAS  Google Scholar 

  198. Tan SK, Sim CS, Goh CL. Hydroquinone-induced exogenous ochronosis in Chinese—two case reports and a review. Int J Dermatol. 2008;47:639–40.

    Article  PubMed  Google Scholar 

  199. Penneys NS. Ochronosislike pigmentation from hydroquinone bleaching creams. Arch Dermatol. 1985;121:1239–40.

    Article  CAS  PubMed  Google Scholar 

  200. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2:213–7.

    Article  CAS  PubMed  Google Scholar 

  201. Srinivas CR, Shenoi SD, Balachandran C. Acceleration of repigmentation in vitiligo by topical minoxidil in patients on photochemotherapy. Int J Dermatol. 1990;29:154–5.

    Article  CAS  PubMed  Google Scholar 

  202. Fiedler-Weiss VC. Potential mechanisms of minoxidil-induced hair growth in alopecia areata. J Am Acad Dermatol. 1987;16:653–6.

    Article  CAS  PubMed  Google Scholar 

  203. Trattner A, David M. Pigmented contact dermatitis from topical minoxidil 5%. Contact Dermat. 2002;46:246.

    Article  CAS  Google Scholar 

  204. Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:601–5.

    Article  CAS  PubMed  Google Scholar 

  205. Cohen PR. Trastuzumab-associated flagellate erythema: report in a woman with metastatic breast cancer and review of antineoplastic therapy-induced flagellate dermatoses. Dermatol Ther. 2015;5:253–64.

    Article  Google Scholar 

  206. Mahmoud BH, Eide MJ. Bendamustine-induced “flagellate dermatitis”. Dermatol Online J. 2012;18:12.

    PubMed  Google Scholar 

  207. Tallon B, Lamb S. Flagellate erythema induced by docetaxel. Clin Exp Dermatol. 2008;33:276–7.

    Article  CAS  PubMed  Google Scholar 

  208. Araki Y, Tamura K, Seita M. Side effects of peplomycin. Cancer Chemother. 1986;13:2446–50.

    CAS  Google Scholar 

  209. Claudy AL, Levigne V, Boucheron S. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine. Dermatology. 1992;184:70–2.

    Article  CAS  PubMed  Google Scholar 

  210. Baselga E, Drolet BA, Casper J, Esterly NB. Chemotherapy-associated supravenous hyperpigmentation. Dermatology. 1996;192:384–5.

    Article  CAS  PubMed  Google Scholar 

  211. Geddes ER, Cohen PR. Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy. South Med J. 2010;103:231–5.

    Article  PubMed  Google Scholar 

  212. Chen GY, Lee JY, Chen WC. Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma. Br J Dermatol. 2005;152:1383–5.

    Article  PubMed  Google Scholar 

  213. Chapman S, Cohen PR. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J. 1997;90:395–8.

    Article  CAS  PubMed  Google Scholar 

  214. Nixon DW. Alterations in nail pigment with cancer chmotherapy. Arch Intern Med. 1976;136:1117–8.

    Article  CAS  PubMed  Google Scholar 

  215. Jeanmougin M, Civatte J, Bonvalet D, Martinet C. Chromonychia and anticancer chemotherapy. Ann Dermatol Venereol. 1982;109:169–72.

    CAS  PubMed  Google Scholar 

  216. James WD, Odom RB. Chemotherapy-induced transverse white lines in the fingernails. Arch Dermatol. 1983;119:334–5.

    Article  CAS  PubMed  Google Scholar 

  217. Shetty MR. White lines in the fingernails induced by combination chemotherapy. BMJ Clin Res Ed. 1988;297:1635.

    Article  CAS  Google Scholar 

  218. Bader-Meunier B, Garel D, Dommergues JP, Venencie PY. Transverse leukonychia and anti-leukemia chemotherapy. Ann Pediatr. 1990;37:337–8.

    CAS  Google Scholar 

  219. Unamuno P, Fernandez-Lopez E, Santos C. Leukonychia due to cytostatic agents. Clin Exp Dermatol. 1992;17:273–4.

    Article  CAS  PubMed  Google Scholar 

  220. Bianchi L, Iraci S, Tomassoli M, Carrozzo AM, Nini G. Coexistence of apparent transverse leukonychia (Muehrcke’s lines type) and longitudinal melanonychia after 5-fluorouracil/adriamycin/cyclophosphamide chemotherapy. Dermatology. 1992;185:216–7.

    Article  CAS  PubMed  Google Scholar 

  221. Hogan PA, Krafchik BR, Boxall L. Transverse striate leukonychia associated with cancer chemotherapy. Pediatr Dermatol. 1991;8:67–8.

    Article  CAS  PubMed  Google Scholar 

  222. Zaun H, Omlor G. Unilateral leukopathia unguis toxica and diffuse hair loss after cytostatic perfusion of an extremity. Der Hautarzt Zeitschr Dermatol Venerol Verwandte Gebiete. 1992;43:215–6.

    CAS  Google Scholar 

  223. Schwartz RA, Vickerman CE. Muehrcke’s lines of the fingernails. Arch Intern Med. 1979;139:242.

    Article  CAS  PubMed  Google Scholar 

  224. Lemez P. Transverse nail ridgings (Beau’s lines) induced by chemotherapy–a dose-dependent phenomenon. Acta Haematol. 1994;92:212–3.

    Article  CAS  PubMed  Google Scholar 

  225. Victoroff VM. Transverse white lines in the fingernails induced by combination chemotherapy. Arch Dermatol. 1993;129:1217–8.

    Article  CAS  PubMed  Google Scholar 

  226. Miles DW, Rubens RD. Images in clinical medicine. Transverse leukonychia. N Engl J Med. 1995;333:100.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Beaumont-Farmington Hills, Farmington Hills, MI, USA

    Amanda F. Nahhas

  2. Department of Dermatology, Henry Ford Hospital, 3031 W. Grand Blvd., Suite 800, Detroit, MI, 48202, USA

    Amanda F. Nahhas, Taylor L. Braunberger & Iltefat H. Hamzavi

Authors
  1. Amanda F. Nahhas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taylor L. Braunberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iltefat H. Hamzavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iltefat H. Hamzavi.

Ethics declarations

Conflict of interest

Dr. Hamzavi is an investigator for Incyte Corporation, Bayer, Estee Lauder, Unigen, Inc., Allergan, and Ferndale Laboratories, with grants received by the institution. Dr. Nahhas and Dr. Braunberger were former sub-investigators for Bayer, Estee Lauder, Unigen, Inc., Allergan, and Ferndale Laboratories, with grants received by their institutions.

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nahhas, A.F., Braunberger, T.L. & Hamzavi, I.H. An Update on Drug-Induced Pigmentation. Am J Clin Dermatol 20, 75–96 (2019). https://doi.org/10.1007/s40257-018-0393-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-018-0393-2

Search

Navigation